Thursday, February 17, 2011
Pacira Pharmaceuticals Inc., of Parsippany, N.J., presented new data from its Phase III bunionectomy study to evaluate the efficacy and safety of the intraoperative administration of Exparel (bupivacaine extended-release liposome injection) at the 57th annual meeting of the Orthopaedic Research Society in Long Beach, Calif.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.